Immutep is a late-stage biotechnology company focused on developing LAG-3-related immunotherapies to treat cancer and autoimmune diseases. The company's lead product, eftilagimod alfa, is a first-in-class antigen-presenting cell agonist designed to activate immune responses against cancer and has advanced through multiple clinical trials in non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer, alongside a pipeline including cancer and autoimmune programs in partnership with companies like Novartis and GSK. Immutep generates revenue through royalties and milestone payments from licensing arrangements—including a deal with EOC Pharma for eftilagimod in China and with Novartis for IMP701—while maintaining research and development capabilities across multiple countries and relying on contract manufacturers and consultants to support clinical development and future commercialization.